Peter Farrell - ResMed Insider

ResMed Inc -- USA Stock  

USD 88.73  0.05  0.0564%

Non-Executive Chairman of the Board

Dr. Peter Farrell, Ph.D. is NonExecutive Chairman of the Board, Founder of the Company. Dr. Farrell also served as chief executive officer from July 1990 until December 2007, and from February 2011 until March 2013. Dr. Farrell served as executive chairman of the board from December 2007 until February 2011, and from March 2013 through December 2013. Since January 1, 2014, he was a nonofficer employee of ResMed. From July 1984 to June 1989, Dr. Farrell served as vice president, research and development at various subsidiaries of Baxter International, Inc., and from August 1985 to June 1989, he also served as managing director of the Baxter Center for Medical Research Pty Ltd., a Baxter subsidiary. From January 1978 to December 1989, he was foundation director of the Graduate School for Biomedical Engineering at the University of New South Wales, where he currently serves as a visiting professor and as chairman of the UNSW Centre for Innovation and Entrepreneurship. He also serves on the Visiting Committee of the Health Sciences Technology Program at the Massachusetts Institute of Technology and on the MIT Dean of Engineerings Advisory Council
Age: 74  Chairman Since 2014  Ph.D    
858 836-5000
Farrell serves on two faculty advisory boards at the University of California, San Diego: the Rady Business School and the Jacobs Engineering School. He holds a B.E. in chemical engineering with honors from the University of Sydney, an S.M. in chemical engineering from the Massachusetts Institute of Technology, a Ph.D. in chemical engineering and bioengineering from the University of Washington, Seattle and a D.Sc. from the University of New South Wales for research contributions in the field of treatment with the artificial kidney. Since 2005, Dr. Farrell was a director of NuVasive, Inc., a NASDAQlisted company which develops and markets products for the surgical treatment of spine disorders. From 2007 through 2014, he was the nonexecutive chairman of the board of QRx Pharma, an ASXlisted specialty pharmaceutical company.

Peter Farrell Latest Insider Activity

Management Efficiency

The company has Return on Asset of 8.72 % which means that on every $100 spent on asset it made $8.72 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 18.43 % implying that it generated $18.43 on every 100 dollars invested.
The company has 1.02 B in debt with debt to equity (D/E) ratio of 49.7 . This implies that the company may be unable to create cash to meet all of its financial commitments. ResMed Inc has Current Ratio of 4.63 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Found 8 records


Daniel StanzioneQuest Diagnostics Incorporated
Jonathan LordDexCom Inc
Thomas BenderThe Cooper Companies Inc
Peter NicholasBoston Scientific Corporation
Terrance GreggDexCom Inc
Allan RubensteinThe Cooper Companies Inc
A BenderThe Cooper Companies Inc

Entity Summary

ResMed Inc. designs, develops, manufactures, and markets medical devices and cloudbased software applications that diagnose, treat, and manage respiratory disorders. ResMed Inc (RMD) is traded on New York Stock Exchange in USA. It is located in CALIFORNIA, U.S.A and employs 5,250 people. ResMed is listed under Medical Equipment category by Fama And French industry classification.

Did you try this?

Run Focused Opportunities Now

Focused Opportunities

Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Hide  View All  NextLaunch Focused Opportunities
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add ResMed Inc to your portfolio

Top Management

ResMed Inc Leadership Team
John Wareham, Director, MBA
Ronald Taylor, Director
Gary Pace, Director, Ph.D
Agnes Lee, Director
Carol Burt, Director
Rich Sulpizio, Director
Peter Farrell, Chairman, Ph.D
Jim Hollingshead, President, Ph.D
Don Darkin, President
Jack Wareham, Director
Anne Reiser, President
Karen Drexler, Director
Richard McHale, President
Donald Darkin, President
Rob Douglas, President
Christopher Roberts, Director, MBA
Chris Roberts, Director, MBA
Robert Douglas, COO
BE Farrell, Chairman
Brett Sandercock, CFO
Ron Taylor, Director
Raj Sodhi, President, MBA
David Pendarvis, Executive
Richard Sulpizio, Director
Michael Farrell, CEO, MBA

Stock Performance

ResMed Performance Indicators